Clinical trial
Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or…
NCT00028002 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00028002 |
|---|---|
| Title | Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor |
| Official title | A Phase II Trial of Neoadjuvant/Adjuvant STI-571 (Gleevec NSC #716051) for Primary and Recurrent Operable Malignant GIST Expressing the KIT Receptor Tyrosine Kinase (CD117) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | American College of Radiology Imaging Network Eastern Cooperative Oncology Group Radiation Therapy Oncology Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastrointestinal Stromal Tumor |
| Intervention type | Drug, Procedure |
| Interventions | Conventional Surgery, Imatinib Mesylate |
| Enrollment | 63 |
| Start date | Mar 31, 2002 |
| Primary completion | Jan 28, 2009 |
| Completion | Jan 28, 2009 |
| First posted | Jan 27, 2003 |
| Last update posted | Oct 26, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: